Pancreatic ductal adenocarcinoma is a complex genetic disease. As might be expected for a malignancy that is rather homogeneous in clinical presentation and behavior, a distinct subset of genes are found to be genetically inactivated in a majority of the tumors. A yet larger subset of genes experien
Genetic susceptibility in pancreatic ductal adenocarcinoma
β Scribed by R. Lochan; A. K. Daly; H. L. Reeves; R. M. Charnley
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 263 KB
- Volume
- 95
- Category
- Article
- ISSN
- 0007-1323
- DOI
- 10.1002/bjs.6049
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Background
The strongest risk factors for pancreatic adenocarcinoma are tobacco smoking and increasing age. However, only a few smokers or elderly individuals develop the disease and genetic factors are also likely to be important.
Methods
The literature on genetic factors modifying susceptibility to cancer was reviewed, with particular regard to the interindividual variation that exists in the development of pancreatic adenocarcinoma.
Results
Tobacco-derived carcinogen-metabolizing enzyme gene variants have been the main area of study in stratifying the risk of sporadic pancreatic cancer. Inconsistent results have emerged from the few molecular epidemiological studies performed.
Conclusion
There is great scope for further investigation of critical pathways and unidentified genetic influences may be revealed. This may eventually allow the identification of individuals at high risk who might be targeted for screening.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND The p53βdependent G2/M checkpoint plays a key role in the maintenance of genomic integrity, thereby protecting cells from neoplastic progression. __Reprimo__, a gene involved in the p53βinduced G2 cell cycle arrest, has been recently identified as a novel target for aberr
Our experiments were designed to identify initial biochemical and biological changes that occur during pancreatic carcinogenesis. TAKA-1, an immortal hamster pancreatic ductal cell line, was treated in vitro for up to 11 weeks with the pancreatic carcinogen N-nitorosobis(2-oxopropyl)amine (BOP). The